[1] Montini G, Tullus K, Hewitt I. Febrile urinary tract infections in children. N Engl J Med. 2011. 365(3): 239-50.
[2] Shaikh N, Mattoo TK, Keren R, et al. Early Antibiotic Treatment for Pediatric Febrile Urinary Tract Infection and Renal Scarring. JAMA Pediatr. 2016. 170(9): 848-54.
[3] Hanna-Wakim RH, Ghanem ST, El HMW, et al. Epidemiology and characteristics of urinary tract infections in children and adolescents. Front Cell Infect Microbiol. 2015. 5: 45.
[4] Zorc JJ, Kiddoo DA, Shaw KN. Diagnosis and management of pediatric urinary tract infections. Clin Microbiol Rev. 2005. 18(2): 417-22.
[5] Moxon CA, Paulus S. Beta-lactamases in Enterobacteriaceae infections in children. J Infect. 2016. 72 Suppl: S41-9.
[6] Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis. J Infect. 2016. 73(6): 547-557.
[7] Sorlozano A, Jimenez-Pacheco A, de Dios Luna Del Castillo J, et al. Evolution of the resistance to antibiotics of bacteria involved in urinary tract infections: a 7-year surveillance study. Am J Infect Control. 2014. 42(10): 1033-8.
[8] Mandal A, Sahi PK. Antimicrobial susceptibility of uropathogens isolated from Cambodian children. Paediatr Int Child Health. 2017. 37(3): 233.
[9] Topaloglu R, Er I, Dogan BG, et al. Risk factors in community-acquired urinary tract infections caused by ESBL-producing bacteria in children. Pediatr Nephrol. 2010. 25(5): 919-25.
[10] Dayan N, Dabbah H, Weissman I, Aga I, Even L, Glikman D. Urinary tract infections caused by community-acquired extended-spectrum beta-lactamase-producing and nonproducing bacteria: a comparative study. J Pediatr. 2013. 163(5): 1417-21.
[11] Megged O. Extended-spectrum beta-lactamase-producing bacteria causing community-acquired urinary tract infections in children. Pediatr Nephrol. 2014. 29(9): 1583-7.
[12] Uyar AN, Ekinci Z, Dundar D, Baydemir C. Childhood urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: Risk factors and empiric therapy. Pediatr Int. 2017. 59(2): 176-180.
[13] Uwaezuoke SN, 0000-0002-2464-6645 AO, Ndu IK, Eze IC. The prevalence and risk of urinary tract infection in malnourished children: a systematic review and meta-analysis. BMC Pediatr. 2019. 19(1): 261.
[14] Ahmed M, Moremi N, Mirambo MM, et al. Multi-resistant gram negative enteric bacteria causing urinary tract infection among malnourished underfives admitted at a tertiary hospital, northwestern, Tanzania. Ital J Pediatr. 2015. 41: 44.
[15] Shin HR, Moon J, Lee HS, et al. Increasing prevalence of antimicrobial resistance in urinary tract infections of neurological patients, Seoul, South Korea, 2007-2016. Int J Infect Dis. 2019. 84: 109-115.
[16] Mori R, Lakhanpaul M, Verrier-Jones K. Diagnosis and management of urinary tract infection in children: summary of NICE guidance. BMJ. 2007. 335(7616): 395-7.
[17] Ladhani S, Gransden W. Increasing antibiotic resistance among urinary tract isolates. Arch Dis Child. 2003. 88(5): 444-5.
[18] Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015. 13(5): 269-84.
[19] Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults. Am Fam Physician. 2005. 71(5): 933-42.
[20] Sorlozano-Puerto A, 0000-0003-0249-2291 AO, Gomez-Luque JM, et al. Etiological and Resistance Profile of Bacteria Involved in Urinary Tract Infections in Young Children. Biomed Res Int. 2017. 2017: 4909452.
[21] Saadeh SA, Mattoo TK. Managing urinary tract infections. Pediatr Nephrol. 2011. 26(11): 1967-76.
[22] Andreu A, Alos JI, Gobernado M, Marco F, de la Rosa M, Garcia-Rodriguez JA. [Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study]. Enferm Infecc Microbiol Clin. 2005. 23(1): 4-9.
[23] Moya-Dionisio V, Diaz-Zabala M, Ibanez-Fernandez A, et al. [Uropathogen pattern and antimicrobial susceptibility in positive urinary cultures isolates from paediatric patients]. Rev Esp Quimioter. 2016. 29(3): 146-50.
[24] Stein R, Dogan HS, Hoebeke P, et al. Urinary tract infections in children: EAU/ESPU guidelines. Eur Urol. 2015. 67(3): 546-58.
[25] Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003. 63(4): 353-65.
[26] Bruchet N, AUID- Oho, Gaschignard J, AUID- Oho, Timsit S, Cheron G. Risk of recurrence in children with a urinary tract infection due to extended-spectrum beta-lactamase producing Enterobacteriaceae. Acta Paediatr. 2020 .
[27] Albaramki JH, AUID- Oho, Abdelghani T, et al. Urinary tract infection caused by extended-spectrum beta-lactamase-producing bacteria: Risk factors and antibiotic resistance. Pediatr Int. 2019. 61(11): 1127-1132.
[28] Tullos JB, AUID- Oho, Stoudenmire LL, Pouliot JD. Piperacillin-Tazobactam Versus Carbapenems for the Treatment of Nonbacteremic Urinary Tract Infections due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae. Hosp Pharm. 2020. 55(1): 44-49.
[29] Poisson SN, Johnston SC, Josephson SA. Urinary tract infections complicating stroke: mechanisms, consequences, and possible solutions. Stroke. 2010. 41(4): e180-4.
[30] Kumar M, Dutta R, Saxena S, Singhal S. Risk Factor Analysis in Clinical Isolates of ESBL and MBL (Including NDM-1) Producing Escherichia coli and Klebsiella Species in a Tertiary Care Hospital. J Clin Diagn Res. 2015. 9(11): DC08-13.
[31] Karam G, Chastre J, Wilcox MH, Vincent JL. Antibiotic strategies in the era of multidrug resistance. Crit Care. 2016. 20(1): 136.
[32] Sakran W, Smolkin V, Odetalla A, Halevy R, Koren A. Community-acquired urinary tract infection in hospitalized children: etiology and antimicrobial resistance. A comparison between first episode and recurrent infection. Clin Pediatr (Phila). 2015. 54(5): 479-83.
[33] Awais M, Rehman A, Baloch NU, Khan F, Khan N. Evaluation and management of recurrent urinary tract infections in children: state of the art. Expert Rev Anti Infect Ther. 2015. 13(2): 209-31.
[34] Stephens GM, Akers S, Nguyen H, Woxland H. Evaluation and management of urinary tract infections in the school-aged child. Prim Care. 2015. 42(1): 33-41.
[35] Dore-Bergeron MJ, Gauthier M, Chevalier I, McManus B, Tapiero B, Lebrun S. Urinary tract infections in 1- to 3-month-old infants: ambulatory treatment with intravenous antibiotics. Pediatrics. 2009. 124(1): 16-22.
[36] Gauthier M, Chevalier I, Sterescu A, Bergeron S, Brunet S, Taddeo D. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center. Pediatrics. 2004. 114(4): e469-76.
[37] Edlin RS, Shapiro DJ, Hersh AL, Copp HL. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J Urol. 2013. 190(1): 222-7.